February 20, 2026 - ChartAlert®

TECHNOE – Q3 FY26 Earnings Call – 11-Feb-26

TECHNOE’s topline growth hinges on digital infra scalability (INR100–400 crore revenue contribution) and EPC discipline (INR3,000–3,500 crore order intake); bottom-line accretion (INR15–75 EPS) requires hyperscaler validation and smart metering cash flows, while margins (14–50% EBITDA) reflect structural shift but face execution and policy risks.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) Hyperscaler onboarding in Chennai/Noida by 1H FY27; (2) Smart metering execution hits 80% of 2.24M target by FY26-end.
Outcome: INR3,400 crore revenue (FY26), INR15 EPS met; data center contributes INR80–100 crore (FY27). EBITDA margins stabilize at 14–15% (EPC) + 50%+ (digital). Capex funded via internal accruals; no equity dilution. Re-rating to 22–24x PE if digital infra scales.

TEXRAIL – Q3 FY26 Earnings Call – 9-Feb-26

TEXRAIL’s topline growth hinges on wheel set resolution and tender execution (50% probability of 12–15% YoY growth), while margins depend on Foundry/private mix scalability (10–11% EBITDA achievable in base case). Cash flow conversion remains the critical swing factor.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Wheel set supply normalizes by Q2 FY27; railway tenders awarded in H1 FY27; Foundry exports hit 15,000 metric tons; private wagon demand grows 10–15% YoY.
Outcome: Revenue grows 12–15% YoY (Rs. 3,800–4,000 crore); EBITDA margins expand to 10–11% (operating leverage, mix shift). OCF turns positive; debt/EBITDA improves. Valuation implication: In line with consensus; rerate on execution visibility.

APOLLOHOSP – Q3 FY26 Earnings Call – 11-Feb-26

Apollo Hospital’s topline likely grows 12–15% in FY’27 (existing hospitals + phased bed additions), but bottomline faces 100–150 bps margin compression from new hospitals; digital profitability and Keimed synergies are binary catalysts for re-rating or de-rating.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key variables: 50% of 750 beds operational by FY’27, digital cash EBITDA breakeven in Q1 FY’27, and 3% pricing power in CONGO-T.
Outcome: Revenue grows 12–14%, EBITDA margins flat YoY (new hospital losses offset by existing hospital expansion). Keimed synergies partially realized; pharmacy delivers 18% same-store growth. Implication: EPS grows 10–12%; FCF breakeven in FY’28.

HINDUNILVR – Q3 FY26 Earnings Call – 12-Feb-26

Hindustan Unilever’s topline growth hinges on mass segment elasticity and quick commerce scalability, while EBITDA resilience depends on liquid premiumization and D2C margin delivery—model 6–8% revenue growth with 23% EBITDA as base, but skew risks to downside if rural demand or commodity pressures materialize.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) Urban consumption recovery (GST 2.0 tailwind, budget stimulus); (2) Benign commodity inflation (palm oil +5%, crude stable).
Outcome: Revenue grows 6–8% (UVG 4–5%) with broad-based category contributions. EBITDA holds at 23% as liquid premiumization and Horlicks relaunch offset QC investments. Signal: Quick commerce reaches 5% of sales with neutral margin impact; D2C brands deliver 20%+ growth.